Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR study of high-dose intermittent sunitinib versus lomustine in recurrent glioblastoma
NL-OMON21711Phase 3Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- Dec 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in glioblastoma (GBM) comparing High-dose intermittent sunitinib with Lomustine control (2 arms). Primary endpoint: Six-month progression-free survival. Planned start Dec 2016; status: not yet recruiting.
02
Drugs
sunitiniblomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON21711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21711.